---
document_datetime: 2025-12-29 13:00:07
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/medicines/human/EPAR/akeega.html
document_name: akeega.html
version: success
processing_time: 0.1054835
conversion_datetime: 2025-12-30 02:42:04.96465
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
# Akeega

[RSS](/en/individual-human-medicine.xml/67663)

##### Authorised

This medicine is authorised for use in the European Union

niraparib / abiraterone acetate Medicine Human Authorised

On Monday, 12 January 2026, between 07:00 and 10:00 CET (Amsterdam time), this website will be unavailable due to scheduled maintenance.

Page contents

## Page contents

- [Overview](#overview)
- [Product information](#product-info)
- [Product details](#product-details)
- [Authorisation details](#authorisation-details)
- [Assessment history](#assessment-history)
- [News on Akeega](#news-on)
- [More information on Akeega](#related-medicines)

- Application under evaluation
- CHMP opinion
- European Commission decision

## Overview

Akeega is a cancer medicine for treating adult patients with castration-resistant prostate cancer that has spread to other parts of the body.

It is used when medical or surgical treatment to lower testosterone levels (castration) has not worked.

Akeega is for patients who have genetic mutations known as BRCA 1/2 mutations and who cannot have chemotherapy. It is used in combination with prednisolone or another medicine prednisone, which is converted into prednisolone.

Akeega contains two active substances: niraparib and abiraterone acetate.

Expand section

Collapse section

## How is Akeega used?

Akeega is available as tablets to be taken by mouth on an empty stomach. The patient should take the medicine once a day for as long as they benefit from it or do not have unacceptable side effects.

The medicine can only be obtained with a prescription. For more information about using Akeega, see the package leaflet or contact your doctor or pharmacist.

## How does Akeega work?

Akeega contains two active substances: niraparib and abiraterone acetate. Niraparib blocks the action of enzymes called PARP-1 and PARP-2, which help to repair damaged DNA in cells when the cells divide to make new cells. The blocking of the PARP enzymes prevents cancer cells from repairing damaged DNA, and, as a result, the cancer cells die.

The other active substance, abiraterone acetate, stops the body producing testosterone by blocking an enzyme called CYP17 found in the testes and elsewhere in the body. Because the cancer needs a supply of testosterone to survive and grow, abiraterone acetate helps slow the growth of the prostate cancer.

## What benefits of Akeega have been shown in studies?

A main study involving 225 patients with castration-resistant prostate cancer and BRCA 1/2 mutations showed that Akeega was effective at slowing the worsening of the disease.

In this study, the time it took for scans to show the disease getting worse was around 17 months in patients who received Akeega, compared to 11 months in those treated with abiraterone acetate plus placebo (a dummy treatment). Patients in both groups also received prednisone.

## What are the risks associated with Akeega?

For the full list of side effects and restrictions with Akeega, see the package leaflet.

The most common side effects with Akeega (which may affect more than 1 in 10 people) include anaemia (low levels of red blood cells), high blood pressure, constipation, tiredness, nausea, thrombocytopenia (low levels of blood platelets), difficulty breathing, back pain, reduced appetite, neutropenia (low levels of neutrophils, a type of white blood cell), joint pain, vomiting, low levels of potassium, dizziness, difficulty sleeping, high blood glucose levels and urinary tract infection.

The most serious side effects include anaemia, high blood pressure, thrombocytopenia, neutropenia and increase levels of the liver enzyme alkaline phosphatase.

Akeega must not be used in patients with severe liver problems and should not be administered in combination with Radium-223, a type of radiotherapy.

Akeega is not for use in women. As it may cause harm to the unborn baby, patients engaged in sexual activity with a woman who is pregnant or can become pregnant should use contraception.

## Why is Akeega authorised in the EU?

The main study showed that Akeega was effective at slowing the worsening of castration-resistant prostate cancer that has spread to other parts of the body in patients with BRCA 1/2 mutations who cannot receive chemotherapy.

Most of side effects of Akeega are those seen when the individual active substances are used alone. Although some side effects were serious, they were generally manageable. The European Medicines Agency therefore decided that the benefits of Akeega are greater than its risks and it can be authorised for use in the EU.

## What measures are being taken to ensure the safe and effective use of Akeega?

The company that markets Akeega will provide further data on how well treatment prolongs patients' lives.

Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Akeega have also been included in the summary of product characteristics and the package leaflet.

As for all medicines, data on the use of Akeega are continuously monitored. Suspected side effects reported with Akeega are carefully evaluated and any necessary action taken to protect patients.

## Other information about Akeega

Akeega received a marketing authorisation valid throughout the EU on 19 April 2023.

Further information on Akeega can be found on the Agency's website: [ema.europa.eu/medicines/human/EPAR/akeega](/en/medicines/human/EPAR/akeega) .

Akeega : EPAR - Medicine overview

Reference Number: EMA/159686/2023

English (EN) (121.04 KB - PDF)

**First published:** 02/06/2023

[View](/en/documents/overview/akeega-epar-medicine-overview_en.pdf)

[Other languages (22)](#file-language-dropdown-25)

български (BG) (144.2 KB - PDF)

**First published:**

02/06/2023

[View](/bg/documents/overview/akeega-epar-medicine-overview_bg.pdf)

español (ES) (121.16 KB - PDF)

**First published:**

02/06/2023

[View](/es/documents/overview/akeega-epar-medicine-overview_es.pdf)

čeština (CS) (141.87 KB - PDF)

**First published:**

02/06/2023

[View](/cs/documents/overview/akeega-epar-medicine-overview_cs.pdf)

dansk (DA) (119.08 KB - PDF)

**First published:**

02/06/2023

[View](/da/documents/overview/akeega-epar-medicine-overview_da.pdf)

Deutsch (DE) (123.13 KB - PDF)

**First published:**

02/06/2023

[View](/de/documents/overview/akeega-epar-medicine-overview_de.pdf)

eesti keel (ET) (107.93 KB - PDF)

**First published:**

02/06/2023

[View](/et/documents/overview/akeega-epar-medicine-overview_et.pdf)

ελληνικά (EL) (144.59 KB - PDF)

**First published:**

02/06/2023

[View](/el/documents/overview/akeega-epar-medicine-overview_el.pdf)

français (FR) (122.1 KB - PDF)

**First published:**

02/06/2023

[View](/fr/documents/overview/akeega-epar-medicine-overview_fr.pdf)

hrvatski (HR) (140.93 KB - PDF)

**First published:**

02/06/2023

[View](/hr/documents/overview/akeega-epar-medicine-overview_hr.pdf)

italiano (IT) (119.97 KB - PDF)

**First published:**

02/06/2023

[View](/it/documents/overview/akeega-epar-medicine-overview_it.pdf)

latviešu valoda (LV) (157.71 KB - PDF)

**First published:**

02/06/2023

[View](/lv/documents/overview/akeega-epar-medicine-overview_lv.pdf)

lietuvių kalba (LT) (142.21 KB - PDF)

**First published:**

02/06/2023

[View](/lt/documents/overview/akeega-epar-medicine-overview_lt.pdf)

magyar (HU) (141.5 KB - PDF)

**First published:**

02/06/2023

[View](/hu/documents/overview/akeega-epar-medicine-overview_hu.pdf)

Malti (MT) (143.69 KB - PDF)

**First published:**

02/06/2023

[View](/mt/documents/overview/akeega-epar-medicine-overview_mt.pdf)

Nederlands (NL) (119.81 KB - PDF)

**First published:**

02/06/2023

[View](/nl/documents/overview/akeega-epar-medicine-overview_nl.pdf)

polski (PL) (143.7 KB - PDF)

**First published:**

02/06/2023

[View](/pl/documents/overview/akeega-epar-medicine-overview_pl.pdf)

português (PT) (121.82 KB - PDF)

**First published:**

02/06/2023

[View](/pt/documents/overview/akeega-epar-medicine-overview_pt.pdf)

română (RO) (138.93 KB - PDF)

**First published:**

02/06/2023

[View](/ro/documents/overview/akeega-epar-medicine-overview_ro.pdf)

slovenčina (SK) (142.1 KB - PDF)

**First published:**

02/06/2023

[View](/sk/documents/overview/akeega-epar-medicine-overview_sk.pdf)

slovenščina (SL) (140.45 KB - PDF)

**First published:**

02/06/2023

[View](/sl/documents/overview/akeega-epar-medicine-overview_sl.pdf)

Suomi (FI) (118.91 KB - PDF)

**First published:**

02/06/2023

[View](/fi/documents/overview/akeega-epar-medicine-overview_fi.pdf)

svenska (SV) (119.11 KB - PDF)

**First published:**

02/06/2023

[View](/sv/documents/overview/akeega-epar-medicine-overview_sv.pdf)

Akeega : EPAR - Risk management plan summary

English (EN) (956.61 KB - PDF)

**First published:** 19/08/2024

[View](/en/documents/rmp-summary/akeega-epar-risk-management-plan-summary_en.pdf-0)

## Product information

Akeega : EPAR - Product Information

English (EN) (849.37 KB - PDF)

**First published:** 02/06/2023

**Last updated:** 19/08/2024

[View](/en/documents/product-information/akeega-epar-product-information_en.pdf)

[Other languages (24)](#file-language-dropdown-461)

български (BG) (571.28 KB - PDF)

**First published:**

02/06/2023

**Last updated:**

19/08/2024

[View](/bg/documents/product-information/akeega-epar-product-information_bg.pdf)

español (ES) (1.01 MB - PDF)

**First published:**

02/06/2023

**Last updated:**

19/08/2024

[View](/es/documents/product-information/akeega-epar-product-information_es.pdf)

čeština (CS) (1.01 MB - PDF)

**First published:**

02/06/2023

**Last updated:**

19/08/2024

[View](/cs/documents/product-information/akeega-epar-product-information_cs.pdf)

dansk (DA) (784.73 KB - PDF)

**First published:**

02/06/2023

**Last updated:**

19/08/2024

[View](/da/documents/product-information/akeega-epar-product-information_da.pdf)

Deutsch (DE) (811.85 KB - PDF)

**First published:**

02/06/2023

**Last updated:**

19/08/2024

[View](/de/documents/product-information/akeega-epar-product-information_de.pdf)

eesti keel (ET) (667.46 KB - PDF)

**First published:**

02/06/2023

**Last updated:**

19/08/2024

[View](/et/documents/product-information/akeega-epar-product-information_et.pdf)

ελληνικά (EL) (977.7 KB - PDF)

**First published:**

02/06/2023

**Last updated:**

19/08/2024

[View](/el/documents/product-information/akeega-epar-product-information_el.pdf)

français (FR) (618.13 KB - PDF)

**First published:**

02/06/2023

**Last updated:**

19/08/2024

[View](/fr/documents/product-information/akeega-epar-product-information_fr.pdf)

hrvatski (HR) (669.23 KB - PDF)

**First published:**

02/06/2023

**Last updated:**

19/08/2024

[View](/hr/documents/product-information/akeega-epar-product-information_hr.pdf)

íslenska (IS) (749.5 KB - PDF)

**First published:**

02/06/2023

**Last updated:**

19/08/2024

[View](/is/documents/product-information/akeega-epar-product-information_is.pdf)

italiano (IT) (675.39 KB - PDF)

**First published:**

02/06/2023

**Last updated:**

19/08/2024

[View](/it/documents/product-information/akeega-epar-product-information_it.pdf)

latviešu valoda (LV) (775.61 KB - PDF)

**First published:**

02/06/2023

**Last updated:**

19/08/2024

[View](/lv/documents/product-information/akeega-epar-product-information_lv.pdf)

lietuvių kalba (LT) (753.58 KB - PDF)

**First published:**

02/06/2023

**Last updated:**

19/08/2024

[View](/lt/documents/product-information/akeega-epar-product-information_lt.pdf)

magyar (HU) (809.56 KB - PDF)

**First published:**

02/06/2023

**Last updated:**

19/08/2024

[View](/hu/documents/product-information/akeega-epar-product-information_hu.pdf)

Malti (MT) (894.9 KB - PDF)

**First published:**

02/06/2023

**Last updated:**

19/08/2024

[View](/mt/documents/product-information/akeega-epar-product-information_mt.pdf)

Nederlands (NL) (956.18 KB - PDF)

**First published:**

02/06/2023

**Last updated:**

19/08/2024

[View](/nl/documents/product-information/akeega-epar-product-information_nl.pdf)

norsk (NO) (829.02 KB - PDF)

**First published:**

02/06/2023

**Last updated:**

19/08/2024

[View](/no/documents/product-information/akeega-epar-product-information_no.pdf)

polski (PL) (742.31 KB - PDF)

**First published:**

02/06/2023

**Last updated:**

19/08/2024

[View](/pl/documents/product-information/akeega-epar-product-information_pl.pdf)

português (PT) (793.06 KB - PDF)

**First published:**

02/06/2023

**Last updated:**

19/08/2024

[View](/pt/documents/product-information/akeega-epar-product-information_pt.pdf)

română (RO) (805.88 KB - PDF)

**First published:**

02/06/2023

**Last updated:**

19/08/2024

[View](/ro/documents/product-information/akeega-epar-product-information_ro.pdf)

slovenčina (SK) (842.7 KB - PDF)

**First published:**

02/06/2023

**Last updated:**

19/08/2024

[View](/sk/documents/product-information/akeega-epar-product-information_sk.pdf)

slovenščina (SL) (919.27 KB - PDF)

**First published:**

02/06/2023

**Last updated:**

19/08/2024

[View](/sl/documents/product-information/akeega-epar-product-information_sl.pdf)

Suomi (FI) (668.54 KB - PDF)

**First published:**

02/06/2023

**Last updated:**

19/08/2024

[View](/fi/documents/product-information/akeega-epar-product-information_fi.pdf)

svenska (SV) (721.34 KB - PDF)

**First published:**

02/06/2023

**Last updated:**

19/08/2024

[View](/sv/documents/product-information/akeega-epar-product-information_sv.pdf)

**Latest procedure affecting product information:** II/0003 11/07/2024

icon globe

<!-- image -->

This medicine's product information is available in all **official EU languages** . Select 'available languages' to access the language you need.

Product information documents contain:

- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).

Akeega : EPAR - All authorised presentations

English (EN) (54.37 KB - PDF)

**First published:** 02/06/2023

[View](/en/documents/all-authorised-presentations/akeega-epar-all-authorised-presentations_en.pdf)

[Other languages (24)](#file-language-dropdown-990)

български (BG) (55.74 KB - PDF)

**First published:**

02/06/2023

[View](/bg/documents/all-authorised-presentations/akeega-epar-all-authorised-presentations_bg.pdf)

español (ES) (54.4 KB - PDF)

**First published:**

02/06/2023

[View](/es/documents/all-authorised-presentations/akeega-epar-all-authorised-presentations_es.pdf)

čeština (CS) (56.64 KB - PDF)

**First published:**

02/06/2023

[View](/cs/documents/all-authorised-presentations/akeega-epar-all-authorised-presentations_cs.pdf)

dansk (DA) (55.39 KB - PDF)

**First published:**

02/06/2023

[View](/da/documents/all-authorised-presentations/akeega-epar-all-authorised-presentations_da.pdf)

Deutsch (DE) (56.11 KB - PDF)

**First published:**

02/06/2023

[View](/de/documents/all-authorised-presentations/akeega-epar-all-authorised-presentations_de.pdf)

eesti keel (ET) (55.22 KB - PDF)

**First published:**

02/06/2023

[View](/et/documents/all-authorised-presentations/akeega-epar-all-authorised-presentations_et.pdf)

ελληνικά (EL) (53.65 KB - PDF)

**First published:**

02/06/2023

[View](/el/documents/all-authorised-presentations/akeega-epar-all-authorised-presentations_el.pdf)

français (FR) (54.29 KB - PDF)

**First published:**

02/06/2023

[View](/fr/documents/all-authorised-presentations/akeega-epar-all-authorised-presentations_fr.pdf)

hrvatski (HR) (54.07 KB - PDF)

**First published:**

02/06/2023

[View](/hr/documents/all-authorised-presentations/akeega-epar-all-authorised-presentations_hr.pdf)

íslenska (IS) (55.18 KB - PDF)

**First published:**

02/06/2023

[View](/is/documents/all-authorised-presentations/akeega-epar-all-authorised-presentations_is.pdf)

italiano (IT) (55.53 KB - PDF)

**First published:**

02/06/2023

[View](/it/documents/all-authorised-presentations/akeega-epar-all-authorised-presentations_it.pdf)

latviešu valoda (LV) (54.74 KB - PDF)

**First published:**

02/06/2023

[View](/lv/documents/all-authorised-presentations/akeega-epar-all-authorised-presentations_lv.pdf)

lietuvių kalba (LT) (55.97 KB - PDF)

**First published:**

02/06/2023

[View](/lt/documents/all-authorised-presentations/akeega-epar-all-authorised-presentations_lt.pdf)

magyar (HU) (55.13 KB - PDF)

**First published:**

02/06/2023

[View](/hu/documents/all-authorised-presentations/akeega-epar-all-authorised-presentations_hu.pdf)

Malti (MT) (56.63 KB - PDF)

**First published:**

02/06/2023

[View](/mt/documents/all-authorised-presentations/akeega-epar-all-authorised-presentations_mt.pdf)

Nederlands (NL) (54.11 KB - PDF)

**First published:**

02/06/2023

[View](/nl/documents/all-authorised-presentations/akeega-epar-all-authorised-presentations_nl.pdf)

norsk (NO) (53.83 KB - PDF)

**First published:**

02/06/2023

[View](/no/documents/all-authorised-presentations/akeega-epar-all-authorised-presentations_no.pdf)

polski (PL) (56.55 KB - PDF)

**First published:**

02/06/2023

[View](/pl/documents/all-authorised-presentations/akeega-epar-all-authorised-presentations_pl.pdf)

português (PT) (54.71 KB - PDF)

**First published:**

02/06/2023

[View](/pt/documents/all-authorised-presentations/akeega-epar-all-authorised-presentations_pt.pdf)

română (RO) (54.69 KB - PDF)

**First published:**

02/06/2023

[View](/ro/documents/all-authorised-presentations/akeega-epar-all-authorised-presentations_ro.pdf)

slovenčina (SK) (56.43 KB - PDF)

**First published:**

02/06/2023

[View](/sk/documents/all-authorised-presentations/akeega-epar-all-authorised-presentations_sk.pdf)

slovenščina (SL) (54.73 KB - PDF)

**First published:**

02/06/2023

[View](/sl/documents/all-authorised-presentations/akeega-epar-all-authorised-presentations_sl.pdf)

Suomi (FI) (55.13 KB - PDF)

**First published:**

02/06/2023

[View](/fi/documents/all-authorised-presentations/akeega-epar-all-authorised-presentations_fi.pdf)

svenska (SV) (53.41 KB - PDF)

**First published:**

02/06/2023

[View](/sv/documents/all-authorised-presentations/akeega-epar-all-authorised-presentations_sv.pdf)

## Product details

Name of medicine Akeega Active substance

- abiraterone acetate
- niraparib (tosilate monohydrate)

International non-proprietary name (INN) or common name

- niraparib
- abiraterone acetate

Therapeutic area (MeSH) Prostatic Neoplasms, Castration-Resistant Anatomical therapeutic chemical (ATC) code L01

### Pharmacotherapeutic group

Antineoplastic agents

### Therapeutic indication

Treatment of adult patients with prostate cancer.

## Authorisation details

EMA product number EMEA/H/C/005932 Marketing authorisation holder

Janssen-Cilag International N.V.

Turnhoutseweg 30

Opinion adopted 23/02/2023 Marketing authorisation issued 19/04/2023 Revision 1

## Assessment history

Expand section

Collapse section

## Changes since initial authorisation of medicine

Akeega : EPAR - Procedural steps taken and scientific information after authorisation

English (EN) (143.88 KB - PDF)

**First published:** 19/08/2024

[View](/en/documents/procedural-steps-after/akeega-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf)

## Initial marketing authorisation documents

Akeega : EPAR - Public assessment report

Adopted

Reference Number: EMA/126335/2023

English (EN) (12.42 MB - PDF)

**First published:** 02/06/2023

[View](/en/documents/assessment-report/akeega-epar-public-assessment-report_en.pdf)

CHMP summary of positive opinion for Akeega

Adopted

Reference Number: EMA/CHMP/55463/2023

English (EN) (167.4 KB - PDF)

**First published:** 24/02/2023

[View](/en/documents/smop-initial/chmp-summary-positive-opinion-akeega_en.pdf)

#### News on Akeega

[Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 20 - 23 February 2023](/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-20-23-february-2023) 24/02/2023

#### More information on Akeega

- [A Post-Authorization Safety Study (PASS) to characterize the risk of secondary primary malignancy including MDS/AML among metastatic prostate cancer patients exposed to AKEEGA (niraparib/abiraterone acetate fixed-dose combination tablet) plus Prednisone/Prednisolone - post-authorisation study](https://catalogues.ema.europa.eu/study/1000000323)

**This page was last updated on** 19/08/2024

## Share this page

[Back to top](#main-content)